Dutasteride and progression of the localized prostate cancer
| Author : Pierre Allain
||Date : 2012-4-21
Dutasteride, Avodart*, is an inhibitor of 5 alpha-reductase inhibiting the bioconversion of testosterone into dihydrotestosterone, to see here.
According to a paper published in The Lancet, 24 March 2012, in patients with a localized prostate cancer, dutasteride 0.5 mg daily slowed the progression of the disease: after three years, a worsening was observed in 38% of the patients treated with dutasteride against 48% in patients with placebo. Adverse sexual effects and gynecomastia were reported in 24% of patients treated by dutasteride against 15% of the patients with placebo; on the cardiovascular system there were no differences but it should be noted that the period of observation was of short duration, three years, and the number of patients included in the study was low, 302.
See a preceding more circumspect analysis concerning the use of dutasteride in prostate cancer.